5ml

Irinocan

IRINOCAN

Irinotecan

Pharmedic Pharmaceuticals Industries (Pvt.) Ltd.

Drug Identity

Active Ingredient
Irinotecan
Drug Class
Antineoplastics
ATC Code
L01CE02
Status
Essential Medicine

How It Works

Administer by IV Infusion, usually over 90 min. D5W (500 ml) is the preferred diluent for most doses. Solutions diluted in NS may precipitate if refrigerated. Dilute in D5W or NS to a final cons of 0.122.8 mg/ml. Due to the relatively acidic pH, irinotecan appears to be more stable in D5W than NS, D5W (500 ml) is the preferred diluent for most doses.

How to Take It

Dosage information not available for this product.

Safety Alerts

Chronic inflammatory bowel disease, bowel obstruction, hepatic impairment, renal impairment, severe myelosuppression

Side Effects

Interstitial pulmonary diseaseacute cholinergic syndrome and delayed diarrhoea (consult product literature)alopeciaanorexiaastheniabone-marrow suppressionextravasationGI effectshyperuricaemiamyelosuppression(dose limiting)nauseaoral mucositisthromboembolismtumourlysis syndromevomiting

Drug Interactions

Neuromuscular blocking agents
carbamazepine
phenobarbital
phenytoin
ketoconazole

Pregnancy & Lactation

Pregnancy
Positive evidence of risk: Avoid
Lactation
Contraindicated. Discontinue breast-feeding

Price Intelligence

Rs 13,182
DRAP approved maximum price · per unit · approved 01 Jul, 2025
No retail price observed for this pack. Retailers may not exceed the approved maximum.
Prices across sources
DRAPper unitRs 13,182

Should you consider an alternative?

Other options containing Irinotecan, and what they are not.

For pharma professionalsCompany, market and opportunity intelligence

Prices as of 30 July 2026 · DRAP ceiling as of 30 July 2026 · schema v3-SKU

For medicine intelligence and professional reference only. Not medical advice.